MRVIMARAVAI LIFESCIENCES HOLDINGS, INC.
Pharmaceutical Preparations
- Revenue
- $186M
- 28% YoY
- Operating margin
- -115.9%
- 27% YoY
- EBITDA
- −$192M
- 11% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $77M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired16% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear21% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $799M | $883M | $289M | $259M | $186M | 28% |
| Operating income | $555M | $574M | −$32M | −$236M | −$215M | 8.6% |
| Net income | $469M | $491M | −$138M | −$145M | −$131M | 9.7% |
| Operating cash flow | $369M | $536M | $126M | $7M | −$58M | 871% |
| Capex | $15M | $17M | $66M | $30M | $13M | 56% |
| Stock-based comp | $10M | $19M | $35M | $49M | $30M | 39% |
| Buybacks | $0 | $0 | — | — | — |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 11 | 131 |
| FY2024 | — | — | 18 | 99 |
| FY2023 | — | — | 22 | 100 |
| FY2022 | — | — | 48 | 97 |
| FY2021 | — | — | 140 | 108 |